Pculin02H, a curcumin derivative, inhibits proliferation and clinical drug resistance of HER2-overexpressing cancer cells

Chemico-Biological Interactions

Volumn 235, Issue , 2015, Pages 17-26

  Lien, Jin Cherng ^a   Hung, Chao Ming ^b   Lin, Yi Jing ^a   Lin, Hui Chang ^a   Ko, Ting Chia ^c   Tseng, Li Chung ^d   Kuo, Sheng Chu ^a   Ho, Chi Tang ^e   Lee, Jang Chang ^a   Way, Tzong Der ^a,f,g  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d TOKO UNIVERSITY   (Taiwan)

^e RUTGERS UNIVERSITY   (United States)

^f NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^g ASIA UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; G2 M arrest; HER2; Pculin02H

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PCULIN 02H; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; G2 PHASE CELL CYCLE CHECKPOINT; M PHASE CELL CYCLE CHECKPOINT; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; PROTEIN PROCESSING; APOPTOSIS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF 7 CELL LINE; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DRUG RESISTANCE; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; RECEPTOR, ERBB-2;

EID: 84928027344     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2015.04.005     Document Type: Article

References (30)

1. C. Basmadjian, Q. Zhao, E. Bentouhami, A. Djehal, C.G. Nebigil, R.A. Johnson, M. Serova, A. de Gramont, S. Faivre, E. Raymond, and L.G. Désaubry Cancer wars: natural products strike back Front. Chem. 2 2014 20
2. H. Ahsan, N. Parveen, N.U. Khan, and S.M. Hadi Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin Chem. Biol. Interact. 121 1999 161 175
3. A. Shehzad, J.W. Park, J. Lee, and Y.S. Lee Curcumin induces radiosensitivity of in vitro and in vivo cancer models by modulating pre-mRNA processing factor 4 Prp4 Chem. Biol. Interact. 206 2013 394 402
4. J.C. Wu, M.L. Tsai, C.S. Lai, Y.J. Wang, C.T. Ho, and M.H. Pan Chemopreventative effects of tetrahydrocurcumin on human diseases Food Funct. 5 2014 12 17
5. A. Zheng, H. Li, X. Wang, Z. Feng, J. Xu, K. Cao, B. Zhou, J. Wu, and J. Liu Anticancer effect of a curcumin derivative B63: ROS production and mitochondrial dysfunction Curr. Cancer Drug Targets 14 2014 156 166
6. V. Basile, S. Belluti, E. Ferrari, C. Gozzoli, S. Ganassi, D. Quaglino, M. Saladini, and C. Imbriano bis-Dehydroxycurcumin triggers mitochondrial-associated cell death in human colon cancer cells through ER-stress induced autophagy PLoS One 8 2013 e53664
7. G.Z. Zhou, S.N. Zhang, L. Zhang, G.C. Sun, and X.B. Chen A synthetic curcumin derivative hydrazinobenzoylcurcumin induces autophagy in A549 lung cancer cells Pharm. Biol. 52 2014 111 116
8. J.S. Shim, J. Lee, H.J. Park, S.J. Park, and H.J. Kwon A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function Chem. Biol. 11 2004 1455 1463
9. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2 2001 127 137
10. M. Yan, B.A. Parker, R. Schwab, and R. Kurzrock HER2 aberrations in cancer: implications for therapy Cancer Treat. Rev. 40 2014 770 780
11. F. Meric-Bernstam, and M.C. Hung Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy Clin. Cancer Res. 12 2006 6326 6330
12. M. Pegram, S. Hsu, G. Lewis, R. Pietras, M. Beryt, M. Sliwkowski, D. Coombs, D. Baly, F. Kabbinavar, and D. Slamon Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 14 1999 2241 2251
13. R.L. Hong, W.H. Spohn, and M.C. Hung Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu Clin. Cancer Res. 5 1999 1884 1891
14. S.H. Sun, H.C. Huang, C. Huang, and J.K. Lin Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin Eur. J. Pharmacol. 690 2012 22 30
15. B. Yadav, S. Taurin, L. Larsen, and R.J. Rosengren RL71, a second-generation curcumin analog, induces apoptosis and downregulates Akt in ER-negative breast cancer cells Int. J. Oncol. 41 2012 1119 1127
16. B. Yadav, S. Taurin, L. Larsen, and R.J. Rosengren RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER-negative breast cancer models Int. J. Oncol. 41 2012 1723 1732
17. E. Meiyanto, D.D. Putri, R.A. Susidarti, R. Murwanti, Sardjiman, A. Fitriasari, U. Husnaa, H. Purnomo, and M. Kawaichi Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation Asian Pac. J. Cancer Prev. 15 2014 179 184
18. D.H. Kuo, M.C. Hung, C.M. Hung, L.M. Liu, F.A. Chen, P.C. Shieh, C.T. Ho, and T.D. Way Body weight management effect of burdock (Arctium lappa L.) root is associated with the activation of AMP-activated protein kinase in HepG2 cell Food Chem. 134 2012 1320 1326
19. T.D. Way, H.Y. Lin, K.T. Hua, J.C. Lee, W.H. Li, M.R. Lee, C.H. Shuang, and J.K. Lin Beneficial effects of different tea flowers against human breast cancer MCF-7 cells Food Chem. 114 2009 1231 1236
20. P.K. Morrow, F. Zambrana, and F.J. Esteva Recent advances in systemic therapy: advances in systemic therapy for HER2-positive metastatic breast cancer Breast Cancer Res. 11 2009 207
21. J.C. Lee, L.C. Chou, J.C. Lien, J.C. Wu, C.H. Huang, C.H. Chung, F.Y. Lee, L.J. Huang, S.C. Kuo, and T.D. Way CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of taxol in vitro and in vivo Oncol. Rep. 30 2013 1762 1772
22. C. O'Brien, G. Cavet, A. Pandita, X. Hu, L. Haydu, S. Mohan, K. Toy, C.S. Rivers, Z. Modrusan, L.C. Amler, and M.R. Lackner Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer Cancer Res. 68 2008 5380 5389
23. G.E. Konecny, N. Venkatesan, G. Yang, J. Dering, C. Ginther, R. Finn, M. Rahmeh, M.S. Fejzo, D. Toft, S.W. Jiang, D.J. Slamon, and K.C. Podratz Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells Br. J. Cancer 98 2008 1076 1084
24. I. Kümler, M.K. Tuxen, and D.L. Nielsen A systematic review of dual targeting in HER2-positive breast cancer Cancer Treat. Rev. 40 2014 259 270
25. E. Felip, J.M. Del Campo, D. Rubio, M.T. Vidal, R. Colomer, and B. Bermejo Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy Cancer 75 1995 2147 2152
26. B.P. Zhou, Y. Liao, W. Xia, Y. Zou, B. Spohn, and M.C. Hung HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation Nat. Cell Biol. 3 2001 973 982
27. J. Luo, B.D. Manning, and L.C. Cantley Targeting the PI3K-Akt pathway in human cancer: rationale and promise Cancer Cell 4 2003 257 262
28. M.M. Hill, and B.A. Hemmings Inhibition of protein kinase B/Akt: implications for cancer therapy Pharmacol. Ther. 93 2002 243 251
29. B.M. Burgering, and R.H. Medema Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty J. Leukoc. Biol. 73 2003 689 701
30. C.S. Mitsiades, N. Mitsiades, and M. Koutsilieris The Akt pathway: molecular targets for anti-cancer drug development Curr. Cancer Drug Targets 4 2004 235 256